Trial
NCT05929664
Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery
Phase IISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Thomas Jefferson University
Collaborators
Regeneron Pharmaceuticals
Condition
Locally Advanced Basal Cell Carcinoma
Intervention
Cemiplimab
Why stopped
Investigational product is not currently available to the study site.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-10